Department of Safety Assessment and Laboratory Animal Resources, Merck & Co, Inc, West Point, PA, USA.
Toxicol Pathol. 2020 Jul;48(5):633-648. doi: 10.1177/0192623320932159.
To date, there has been very little published data evaluating the performance of novel urinary kidney biomarkers in nonhuman primates (NHPs). To assess the biomarker performance and characterize the corresponding histomorphologic patterns of tubular renal injury in the NHP, several studies were conducted using mechanistically diverse nephrotoxicants including cefpirome, cisplatin, naproxen, cyclosporine, and a combination of gentamicin with everninomicin. An evaluation of 10 urinary biomarkers (albumin, clusterin, cystatin C, kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, liver-type fatty acid-binding protein, N-acetyl-β-D-glucosaminidase, osteopontin, retinol binding protein 4 and total protein) was performed on urine collected from these studies. Each of these 5 treatments resulted in kidney proximal tubule injury of various severities. Histomorphologic features observed following treatment were generally consistent with analogous drug-induced changes in humans described in the literature. Most of the analyzed biomarkers were able to detect the injury earlier and with greater sensitivity than blood urea nitrogen and serum creatinine. Across all studies, KIM-1 and clusterin showed the highest overall performance. Differences in the patterns of biomarker responsiveness were noted among certain studies that may be informing tubular injury severity and recovery potential, underlying histopathologic processes, and prognosis. These findings demonstrate the utility of urinary kidney translational safety biomarkers in NHPs and provide additional supporting evidence for translating these biomarkers for use in clinical trial settings to further ensure patient safety.
迄今为止,评估新型尿液肾生物标志物在非人类灵长类动物(NHP)中的性能的已发表数据非常有限。为了评估生物标志物的性能,并描述 NHP 肾小管肾损伤的相应组织形态学模式,使用多种机制不同的肾毒性剂进行了几项研究,包括头孢吡肟、顺铂、萘普生、环孢素以及庆大霉素与埃博霉素的组合。对这些研究中收集的尿液进行了 10 种尿液生物标志物(白蛋白、簇集素、胱抑素 C、肾损伤分子 1、中性粒细胞明胶酶相关脂质运载蛋白、肝型脂肪酸结合蛋白、N-乙酰-β-D-氨基葡萄糖苷酶、骨桥蛋白、视黄醇结合蛋白 4 和总蛋白)的评估。这 5 种治疗方法中的每一种都导致了不同严重程度的肾近端小管损伤。治疗后观察到的组织形态学特征通常与文献中描述的类似药物在人类中引起的变化一致。大多数分析的生物标志物能够更早且更敏感地检测到损伤,比血尿素氮和血清肌酐更敏感。在所有研究中,KIM-1 和簇集素表现出最高的整体性能。在某些研究中,生物标志物反应模式的差异可能提示肾小管损伤的严重程度和恢复潜力、潜在的组织病理学过程和预后。这些发现证明了尿液肾转化安全性生物标志物在 NHP 中的实用性,并为将这些生物标志物进一步转化用于临床试验设置以进一步确保患者安全提供了额外的支持证据。